Ahead of European Cannabis Week, Pierre van Weperen, Managing Director of Grow Group, discusses the current state and future of medical cannabis in the UK. With over 6.4 million individuals on NHS waiting lists, many face extended delays for treatments related to chronic pain, endometriosis, ADHD, and PTSD. This situation has serious consequences, including job losses, worsening mental health, and increased dependency on ineffective treatments. As a result, a growing number of patients are exploring alternative options, including medical cannabis.
During the upcoming UK State of Play Session at Cannabis Europa, van Weperen will address how cannabis-based medicine might alleviate pressing challenges in the healthcare system and help patients regain control over their health. He emphasizes that medical cannabis provides a necessary alternative for those frustrated with the care offered by public health services. ‘We are in the midst of a public health crisis, and the NHS will not resolve it,’ he states. ‘Millions are on waiting lists, and even those receiving treatment often find results lacking.’
Van Weperen notes that many patients, frustrated with their treatment options, resort to spending money on supplements that offer little benefit. He believes an empowered patient should seek solutions rather than remain on a waiting list.
He also points out the complexities faced by private medical cannabis clinics. While these clinics are becoming more affordable, the regulatory environment is cumbersome. Van Weperen describes the current regulatory framework as ‘not fit for purpose.’ He highlights that as the number of patients increases, cannabis is still treated differently than other unlicensed medicines, creating additional costs and delays for businesses, which ultimately impacts patient access.
‘We can’t advertise cannabis-based treatments due to strict regulations, so many patients remain unaware of their options and may turn to the black market,’ van Weperen explains. ‘This leads them to potentially dangerous products.’
The Home Office recently tasked the Advisory Council on the Misuse of Drugs (ACMD) to evaluate whether the 2018 legislative changes have achieved their goals. However, van Weperen remains skeptical about the NHS integrating cannabis-based medicines in the near future. He points out that many government officials do not understand the differences between CBD and medical cannabis and are hesitant to support cannabis for fear of opening the door to other therapies, such as psilocybin and ketamine.
Despite the obstacles, van Weperen is optimistic about the future of medical cannabis in the UK. ‘In five years, I want to see 500,000 patients benefiting from medical cannabis, maintaining their jobs, reconnecting with their families, and contributing positively to society,’ he asserts. He emphasizes that the focus should not be on the industry’s growth but rather on the patients who can benefit from these treatments. ‘The companies that prioritize patient care will lead the way, and I want Grow Group to be part of that movement.’
Join van Weperen at the UK State of Play Session at Cannabis Europa in London on June 24 for further discussion on these important issues. The European cannabis industry is gearing up for European Cannabis Week, taking place from June 19-25, featuring key discussions from industry leaders.
English 
Spanish 
German 
Czech